Xponance LLC Buys 4,436 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Xponance LLC increased its Thermo Fisher Scientific stake by 8.1% in the fourth quarter, buying 4,436 additional shares and bringing its total holding to 59,295 shares worth about $34.4 million.
• Thermo Fisher continues to attract significant institutional interest, with several other funds raising positions and institutional investors owning 89.23% of the company’s stock.
• The company reported strong quarterly results, topping analyst expectations on both earnings and revenue, while also announcing a quarterly dividend of $0.47 per share payable on July 15.

Xponance LLC boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 8.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 59,295 shares of the medical research company's stock after purchasing an additional 4,436 shares during the quarter. Xponance LLC's holdings in Thermo Fisher Scientific were worth $34,358,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in TMO. Assetmark Inc. raised its holdings in shares of Thermo Fisher Scientific by 22.9% in the 4th quarter. Assetmark Inc. now owns 37,654 shares of the medical research company's stock valued at $21,819,000 after acquiring an additional 7,023 shares in the last quarter. Cornerstone Investment Partners LLC purchased a new stake in shares of Thermo Fisher Scientific in the 3rd quarter valued at about $41,393,000. Mackenzie Financial Corp raised its holdings in shares of Thermo Fisher Scientific by 29.4% in the 3rd quarter. Mackenzie Financial Corp now owns 276,545 shares of the medical research company's stock valued at $134,130,000 after acquiring an additional 62,790 shares in the last quarter. NEOS Investment Management LLC raised its holdings in shares of Thermo Fisher Scientific by 28.6% in the 3rd quarter. NEOS Investment Management LLC now owns 51,364 shares of the medical research company's stock valued at $24,913,000 after acquiring an additional 11,415 shares in the last quarter. Finally, Factory Mutual Insurance Co. raised its holdings in shares of Thermo Fisher Scientific by 2.6% in the 3rd quarter. Factory Mutual Insurance Co. now owns 98,935 shares of the medical research company's stock valued at $47,985,000 after acquiring an additional 2,500 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Analyst Ratings Changes

TMO has been the topic of several recent analyst reports. KeyCorp reaffirmed an "overweight" rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Wall Street Zen cut Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Saturday, May 9th. Wolfe Research started coverage on Thermo Fisher Scientific in a report on Tuesday, June 2nd. They set an "outperform" rating and a $535.00 price objective on the stock. Barclays decreased their price objective on Thermo Fisher Scientific from $650.00 to $625.00 and set an "overweight" rating on the stock in a report on Tuesday, April 14th. Finally, Stifel Nicolaus decreased their price objective on Thermo Fisher Scientific from $700.00 to $600.00 and set a "buy" rating on the stock in a report on Friday, April 24th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have issued a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $608.95.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the sale, the chief operating officer directly owned 25,051 shares in the company, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $475.12 on Friday. The firm has a market cap of $176.56 billion, a PE ratio of 26.12, a price-to-earnings-growth ratio of 2.13 and a beta of 0.88. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $643.99. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. The business has a 50 day moving average price of $479.68 and a 200-day moving average price of $528.09.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating analysts' consensus estimates of $5.25 by $0.19. The firm had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The business's quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be given a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, June 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.34%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.